Novartis discontinues clinical trial of Tasigna®
- Details
- Category: Novartis
Novartis is discontinuing a Phase III trial of Tasigna® (nilotinib) for investigational use in the first-line treatment of gastrointestinal stromal tumors (GIST) based on the recommendation of an independent data monitoring committee.
Boehringer Ingelheim maintains sales level/course set for the future: product pipeline well-filled
- Details
- Category: Boehringer Ingelheim
In the business year 2010, Boehringer Ingelheim almost compensated for the anticipated loss of turnover announced in advance last year, nearly achieving the previous year's level.
Pfizer and Medivation Announce Results from Phase 3 HORIZON Trial of Dimebon in Huntington Disease
- Details
- Category: Pfizer
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced results from the Phase 3 HORIZON trial of the investigational drug dimebon (latrepirdine*) in patients with Huntington disease. Dimebon did not achieve statistical significance for either of the co-primary endpoints,
Bayer and Regeneron Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
- Details
- Category: Bayer
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. have initiated the first of two Phase 3 clinical trials evaluating the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution), an investigational new agent for the treatment of certain eye diseases, in the treatment of Diabetic Macular Edema (DME).
Amgen Establishes Commercial Operations in Brazil
- Details
- Category: Amgen
Amgen (NASDAQ: AMGN), the world's largest biotechnology company, announced the expansion of its operations in Brazil, including the acquisition of Bergamo, a privately-held Brazilian pharmaceutical company.
Novartis sells global rights to Elidel®, a medicine to treat atopic dermatitis
- Details
- Category: Novartis
Novartis has signed an agreement to sell to Meda the global rights to manufacture, market and commercialize Elidel® (pimecrolimus) Cream 1%, a medicine to treat mild to moderate atopic dermatitis.
FDA approves orphan drug vandetanib
- Details
- Category: AstraZeneca
AstraZeneca today announced that the US Food and Drug Administration (FDA) approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.
More Pharma News ...
- Sanofi-aventis Successfully Completes Exchange Offer for Genzyme Corporation
- Pfizer to Sell Capsugel to KKR
- Boehringer Ingelheim's lead hepatitis C compound moves into phase III
- GSK publishes payments for research, consulting and advising by US healthcare professionals
- Pfizer Posts Details Of Interactions With U.S. Health Care Professionals And Researchers In 2010
- REACT study to evaluate impact of Daxas® (roflumilast) in patients receiving standard COPD treatment
- Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective